Pelletier is currently CEO, president and an executive director, at Evofem, which is a clinical-stage biopharmaceutical company focused on women’s sexual and reproductive health. She is leading that firm's effort to bring Phexxi, a new, non-hormonal contraceptive candidate, to women. Pelletier was named San Diego Business Journal's 2019 Businesswoman of the Year.
READ: TRACON Pharmaceuticals requests FDA meeting to discuss pivotal study design for Envafolimab to treat sarcoma
"We are very pleased to welcome Saundra to the TRACON Board," Dr Charles Theuer, the president and CEO of San Diego-based TRACON said in a statement.
"Her strong track record of successful strategic, operational and financial management, combined with her vast commercial experience will be invaluable to TRACON as we execute on our plan to complete clinical development and commercialize envafolimab in the United States by 2023."
TRACON is advancing targeted therapies for cancer and its clinical-stage pipeline includes Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed to treat sarcoma.
"TRACON has a first-class management team, an efficient platform to conduct global clinical trials, and a promising drug candidate with near-term commercial potential in envafolimab,” Pelletier commented.
"As a cancer survivor and woman’s health advocate, I am thrilled to support TRACON’s mission and help advance its broad oncology pipeline, which has the potential to address significant unmet needs across multiple tumor types.”
Shares nudged up 3.6% in New York to US$1.15 each.
Contact the author at [email protected]